Cocrystal Pharma Inc (COCP)
1.77
+0.06
(+3.51%)
USD |
NASDAQ |
Sep 27, 16:00
1.74
-0.03
(-1.69%)
After-Hours: 20:00
Cocrystal Pharma SG&A Expense (Annual): 5.99M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.99M |
| December 31, 2022 | 5.745M |
| December 31, 2021 | 5.427M |
| December 31, 2020 | 5.566M |
| December 31, 2019 | 4.863M |
| December 31, 2018 | 4.352M |
| December 31, 2017 | 2.44M |
| December 31, 2016 | 4.14M |
| December 31, 2015 | 6.765M |
| Date | Value |
|---|---|
| December 31, 2014 | 1.737M |
| December 31, 2013 | 0.219M |
| December 31, 2012 | 2.064M |
| December 31, 2011 | 6.149M |
| December 31, 2010 | 6.617M |
| December 31, 2009 | 0.0428M |
| December 31, 2008 | 0.0559M |
| December 31, 2007 | 0.0615M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
4.863M
Minimum
2019
5.99M
Maximum
2023
5.518M
Average
5.566M
Median
2020
SG&A Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.06M |
| Alaunos Therapeutics Inc | 12.22M |
| Oragenics Inc | 5.452M |
| Cara Therapeutics Inc | 27.65M |
| Jaguar Health Inc | 23.05M |